In the latest development for Recursion Pharmaceuticals (RXRX, Financial), Needham analyst Gil Blum has reiterated a "Buy" rating on the stock. This decision reflects continued confidence in the company's future prospects and growth potential.
On July 8th, 2025, the analyst reaffirmed the price target for Recursion Pharmaceuticals (RXRX, Financial) at $8.00 USD, maintaining the same target as previously set. The price target has not changed from its prior level, suggesting stable expectations for the stock's performance.
The consistent "Buy" rating and maintained price target indicate a positive outlook for Recursion Pharmaceuticals (RXRX, Financial) from Needham. Investors may find this reiteration supportive when considering their positions in the biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Recursion Pharmaceuticals Inc (RXRX, Financial) is $6.67 with a high estimate of $10.00 and a low estimate of $4.00. The average target implies an upside of 22.32% from the current price of $5.45. More detailed estimate data can be found on the Recursion Pharmaceuticals Inc (RXRX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Recursion Pharmaceuticals Inc's (RXRX, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Recursion Pharmaceuticals Inc (RXRX, Financial) in one year is $9.39, suggesting a upside of 72.29% from the current price of $5.45. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Recursion Pharmaceuticals Inc (RXRX) Summary page.
